Related Experiment Video
Updated: May 22, 2026
A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Long-acting reversible contraception method use among Title X providers and non-Title X providers in California
Hye-Youn Park1, Maria I Rodriguez, Denis Hulett
1Bixby Center for Global Reproductive Health, University of California, San Francisco, P.O. Box 997420, MS8400, Sacramento, CA 95899-7420, USA.
Background:
Publicly funded family planning services play an important role in reducing unintended pregnancy by providing access to effective contraception. We assessed whether California family planning providers receiving federal Title X funds are more likely to offer on-site long-acting reversible contraception (LARC) methods than those who do not receive these funds.
Study Design:
Using 2009 administrative data, we examined on-site utilization of LARC by clinic type (Title X public, non-Title X public, or private) and constructed beta-binomial logistic regression models.
Results:
The odds of on-site LARC services in non-Title X public and private providers were decreased by 35% [Odds Ratio (OR)=0.65, 95% confidence interval (CI) 0.54-0.79] and 61% [OR=0.39, 95% CI 0.32-0.47], respectively, compared to those of Title X providers after controlling for clinic size, urban/rural location, and proportion of teen, African-American, and Latina clients.
Conclusions:
On-site utilization of LARC is a potential quality indicator for family planning programs. Title X resources are associated with increased use of LARC.
Related Concept Videos
01:22Birth Control Methods
01:21Intrauterine Drug Delivery Systems
01:26Oral Drug Delivery Systems: Continuous-Release Systems
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:18Transdermal Drug Delivery Systems
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...